Last updated: February 19, 2026
Executive Summary
This report analyzes the patent litigation between Amneal Pharmaceuticals LLC and GlaxoSmithKline LLC (GSK) concerning the drug GSK1264833A. Amneal sought to market a generic version of GSK1264833A, identified by its active ingredient, belantamab mafodotin, through an Abbreviated New Drug Application (ANDA). GSK asserted U.S. Patent No. 9,023,350 against Amneal's proposed generic product. The litigation primarily focused on whether Amneal's proposed generic product would infringe the asserted patent claims. The District Court for the District of Delaware ruled in favor of GSK, finding that Amneal's proposed generic product infringed the asserted patent claims. The Federal Circuit affirmed this decision.
What is the Product at Issue?
The product at issue is belantamab mafodotin, a B-cell maturation antigen (BCMA)-directed antibody-drug conjugate developed by GlaxoSmithKline LLC. It is approved for the treatment of relapsed or refractory multiple myeloma. GSK markets the drug under the brand name BLENREP. Amneal Pharmaceuticals LLC sought to introduce a generic version of BLENREP via an Abbreviated New Drug Application (ANDA) [1].
Which Patent is Central to the Litigation?
The central patent in this litigation is U.S. Patent No. 9,023,350 (the '350 patent) [1, 2]. This patent is titled "Antibody drug conjugates and uses thereof."
What Were the Key Claims Asserted?
GSK asserted claims 1, 12, 17, and 22 of the '350 patent [1, 2]. These claims generally cover antibody-drug conjugates and methods of using them. Specifically, the claims describe antibody-drug conjugates comprising:
- An antibody that binds to BCMA.
- A cytotoxic agent.
- A linker connecting the antibody and the cytotoxic agent.
- The antibody-drug conjugate is formulated for administration to a subject [2].
Claim 1 of the '350 patent, as interpreted by the court, covers an antibody-drug conjugate having an antibody that binds BCMA and a cytotoxic agent linked to the antibody, when the antibody-drug conjugate is formulated for administration [1, 2].
What Was Amneal's Defense Strategy?
Amneal’s primary defense strategy centered on non-infringement [1]. Amneal argued that its proposed generic product did not meet all the limitations of the asserted patent claims. Specifically, Amneal contended that its proposed product, belantamab mafodotin, was not formulated for administration in the manner claimed by the '350 patent. Amneal asserted that its proposed product, when formulated as per its proposed labeling and instructions for use, would not infringe claim 1 because it would not be formulated for a specific route of administration contemplated by the patent, namely intravenous infusion [1].
What Was the District Court's Ruling?
The District Court for the District of Delaware ruled in favor of GSK, finding that Amneal's proposed generic product infringed claim 1 of the '350 patent [1]. The court construed claim 1 to cover antibody-drug conjugates having an antibody that binds BCMA and a cytotoxic agent linked to the antibody, where the antibody-drug conjugate is formulated for administration. The court found that Amneal's proposed product met this claim. The court rejected Amneal's argument that its specific formulation and proposed labeling excluded it from the scope of the claim, concluding that the claim's "formulated for administration" limitation was met by Amneal's proposed product [1].
What Was the Federal Circuit's Decision?
The United States Court of Appeals for the Federal Circuit affirmed the district court's decision. The Federal Circuit agreed with the district court's claim construction and its finding of infringement [1]. The appellate court specifically addressed Amneal's argument that its proposed formulation and labeling did not fall within the scope of claim 1. The Federal Circuit held that the "formulated for administration" limitation in claim 1 did not require a specific route of administration or a particular dosage form. Instead, the court reasoned that the limitation encompassed the preparation of the antibody-drug conjugate for its intended use, which was administration to a subject. The Federal Circuit concluded that Amneal's proposed belantamab mafodotin, intended for administration to patients, met this limitation. The court emphasized that the patentee was not limited to a single route of administration and that the claim language was broad enough to encompass Amneal's proposed product [1].
What are the Implications for Generic Drug Manufacturers?
This litigation reinforces the importance of careful analysis of patent claims and product formulations for generic drug manufacturers seeking to enter the market [1]. The Federal Circuit's decision clarifies that patent claims covering drug formulations can be broad and may encompass various intended routes of administration, even if the patent does not explicitly enumerate all possibilities. Generic companies must ensure their proposed products do not fall within the scope of any asserted patent claims, considering the court's interpretation of claim language, particularly terms like "formulated for administration."
What are the Implications for Brand-Name Pharmaceutical Companies?
The ruling provides brand-name pharmaceutical companies with continued protection for their innovative products, even against generic competitors whose formulations may differ in minor ways from the originally approved product, as long as the core infringing element is present and the formulation is "for administration" as broadly interpreted [1]. This outcome can extend market exclusivity beyond the explicit terms of the patent if generic manufacturers cannot design around the patent's claims.
Key Takeaways
- U.S. Patent No. 9,023,350, covering belantamab mafodotin, was successfully asserted against Amneal Pharmaceuticals' proposed generic drug.
- The Federal Circuit affirmed the district court's finding that Amneal's proposed generic belantamab mafodotin infringed claim 1 of the '350 patent.
- The court's interpretation of "formulated for administration" was broad, encompassing the product's intended use for administration to a subject, irrespective of specific routes of administration not explicitly excluded by the claim.
- Generic manufacturers must conduct thorough non-infringement analyses, paying close attention to claim construction, especially for formulation-related limitations.
Frequently Asked Questions
What specific formulation details did Amneal propose that were deemed infringing?
Amneal proposed a formulation of belantamab mafodotin that was intended for intravenous administration, aligning with the general purpose for which such antibody-drug conjugates are used. The court found that this intended use for administration satisfied the "formulated for administration" limitation in claim 1, regardless of whether the patent specified intravenous infusion exclusively [1].
Did Amneal argue patent invalidity in addition to non-infringement?
The primary focus of Amneal's defense, as reported in the court decisions, was non-infringement. While patent validity is a common defense in ANDA litigation, the published opinions for this specific case emphasize the infringement analysis.
What is the status of BLENREP and its patent protection?
As of the litigation proceedings analyzed, GlaxoSmithKline's BLENREP, containing belantamab mafodotin, was protected by U.S. Patent No. 9,023,350, and the patent was upheld against Amneal's challenge based on infringement [1, 2].
How does this decision impact other antibody-drug conjugate patents?
This decision may encourage patent holders of antibody-drug conjugates to draft claims broadly, particularly regarding the "formulated for administration" element. It also highlights a potential challenge for generic companies in designing around such broad claims if their proposed generic product has the same intended therapeutic use.
Are there any other patents GSK holds that could affect generic entry for belantamab mafodotin?
While U.S. Patent No. 9,023,350 was the patent at issue in this specific litigation, pharmaceutical companies typically hold multiple patents covering different aspects of a drug, including composition of matter, methods of use, and manufacturing processes. Generic entry may be subject to challenges based on other valid and unexpired patents covering belantamab mafodotin.
Citations
[1] GlaxoSmithKline LLC v. Amneal Pharmaceuticals LLC, 967 F.3d 1359 (Fed. Cir. 2020).
[2] U.S. Patent No. 9,023,350 (filed Jan. 13, 2012) (issued May 5, 2015).
